Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antihypertensive Agents | 18 | 2019 | 338 | 3.950 |
Why?
|
Hypertension | 16 | 2019 | 899 | 2.930 |
Why?
|
Blood Pressure | 16 | 2019 | 803 | 2.710 |
Why?
|
Practice Guidelines as Topic | 5 | 2018 | 373 | 2.120 |
Why?
|
Blood Pressure Determination | 8 | 2019 | 94 | 1.930 |
Why?
|
Cardiology | 3 | 2018 | 71 | 1.810 |
Why?
|
Hemochromatosis | 20 | 2009 | 70 | 1.700 |
Why?
|
American Heart Association | 3 | 2018 | 83 | 1.360 |
Why?
|
Histocompatibility Antigens Class I | 17 | 2009 | 58 | 1.060 |
Why?
|
Weight Loss | 12 | 2017 | 413 | 1.050 |
Why?
|
Ferritins | 14 | 2008 | 46 | 0.980 |
Why?
|
Diabetes Mellitus, Type 2 | 14 | 2017 | 1374 | 0.950 |
Why?
|
Membrane Proteins | 17 | 2009 | 256 | 0.950 |
Why?
|
Iron Overload | 13 | 2009 | 37 | 0.940 |
Why?
|
Humans | 105 | 2019 | 29013 | 0.770 |
Why?
|
Dementia | 2 | 2019 | 233 | 0.720 |
Why?
|
Sleep Apnea, Obstructive | 6 | 2017 | 46 | 0.720 |
Why?
|
Middle Aged | 66 | 2019 | 10805 | 0.670 |
Why?
|
Female | 84 | 2019 | 18114 | 0.640 |
Why?
|
Advisory Committees | 1 | 2017 | 32 | 0.630 |
Why?
|
Aged | 55 | 2019 | 9462 | 0.610 |
Why?
|
Male | 73 | 2019 | 17768 | 0.610 |
Why?
|
Disease Management | 1 | 2017 | 114 | 0.590 |
Why?
|
Electroconvulsive Therapy | 5 | 2012 | 25 | 0.580 |
Why?
|
Transferrin | 11 | 2007 | 32 | 0.570 |
Why?
|
Adult | 45 | 2019 | 8391 | 0.540 |
Why?
|
Estrogen Replacement Therapy | 10 | 2008 | 182 | 0.520 |
Why?
|
Renal Insufficiency, Chronic | 5 | 2018 | 266 | 0.490 |
Why?
|
Cardiovascular Diseases | 10 | 2019 | 1007 | 0.440 |
Why?
|
Polymorphism, Genetic | 5 | 2010 | 196 | 0.440 |
Why?
|
Iron | 9 | 2009 | 113 | 0.420 |
Why?
|
Clinical Trials as Topic | 3 | 2016 | 298 | 0.420 |
Why?
|
Models, Statistical | 3 | 2006 | 160 | 0.410 |
Why?
|
United States | 12 | 2018 | 3604 | 0.390 |
Why?
|
Obesity | 9 | 2017 | 1062 | 0.390 |
Why?
|
Life Style | 7 | 2017 | 363 | 0.370 |
Why?
|
Data Interpretation, Statistical | 3 | 2000 | 103 | 0.360 |
Why?
|
Genotype | 16 | 2010 | 735 | 0.320 |
Why?
|
Homozygote | 10 | 2009 | 57 | 0.320 |
Why?
|
Mass Screening | 8 | 2009 | 223 | 0.320 |
Why?
|
Cation Transport Proteins | 2 | 2007 | 24 | 0.320 |
Why?
|
Coronary Disease | 5 | 2012 | 197 | 0.320 |
Why?
|
Severity of Illness Index | 15 | 2018 | 863 | 0.310 |
Why?
|
Overweight | 5 | 2017 | 256 | 0.300 |
Why?
|
Psoriasis | 8 | 1999 | 334 | 0.300 |
Why?
|
Seizures | 3 | 1998 | 61 | 0.290 |
Why?
|
Multicenter Studies as Topic | 3 | 2009 | 92 | 0.290 |
Why?
|
Image Processing, Computer-Assisted | 3 | 2007 | 241 | 0.290 |
Why?
|
Mutation | 9 | 2009 | 466 | 0.280 |
Why?
|
Postmenopause | 9 | 2009 | 397 | 0.280 |
Why?
|
Coronary Artery Disease | 5 | 2008 | 358 | 0.270 |
Why?
|
Treatment Outcome | 11 | 2018 | 3099 | 0.260 |
Why?
|
Risk Reduction Behavior | 3 | 2018 | 115 | 0.260 |
Why?
|
Mental Disorders | 3 | 2003 | 103 | 0.260 |
Why?
|
Diet, Reducing | 3 | 2014 | 90 | 0.260 |
Why?
|
Carbamates | 1 | 2004 | 14 | 0.250 |
Why?
|
Metformin | 1 | 2004 | 19 | 0.250 |
Why?
|
European Continental Ancestry Group | 7 | 2009 | 1131 | 0.250 |
Why?
|
Risk Factors | 13 | 2018 | 3509 | 0.240 |
Why?
|
Internet | 1 | 2005 | 156 | 0.240 |
Why?
|
Estrogens, Conjugated (USP) | 5 | 2009 | 125 | 0.240 |
Why?
|
Decision Support Techniques | 1 | 2005 | 104 | 0.240 |
Why?
|
Cholesterol, HDL | 4 | 2012 | 164 | 0.240 |
Why?
|
Piperidines | 1 | 2004 | 125 | 0.230 |
Why?
|
Medroxyprogesterone Acetate | 5 | 2009 | 89 | 0.230 |
Why?
|
Electroencephalography | 4 | 1998 | 71 | 0.230 |
Why?
|
Hypoglycemic Agents | 1 | 2004 | 175 | 0.230 |
Why?
|
Comorbidity | 4 | 2018 | 539 | 0.230 |
Why?
|
Adolescent Health Services | 1 | 2003 | 11 | 0.230 |
Why?
|
Research Design | 4 | 2003 | 285 | 0.230 |
Why?
|
Magnetic Resonance Imaging | 3 | 1999 | 1218 | 0.220 |
Why?
|
Mental Health Services | 1 | 2003 | 24 | 0.220 |
Why?
|
Aftercare | 1 | 2003 | 28 | 0.220 |
Why?
|
Genetic Testing | 5 | 2009 | 89 | 0.220 |
Why?
|
Aged, 80 and over | 16 | 2019 | 3712 | 0.210 |
Why?
|
Brain | 4 | 1998 | 930 | 0.210 |
Why?
|
Suicide, Attempted | 5 | 2001 | 29 | 0.210 |
Why?
|
Quality of Life | 7 | 2012 | 815 | 0.200 |
Why?
|
Cerebrovascular Circulation | 3 | 1998 | 95 | 0.200 |
Why?
|
Lipoproteins, HDL | 3 | 2014 | 247 | 0.190 |
Why?
|
Exercise | 4 | 2013 | 587 | 0.190 |
Why?
|
Health Services Accessibility | 1 | 2003 | 231 | 0.190 |
Why?
|
Sleep, REM | 2 | 2017 | 6 | 0.190 |
Why?
|
Biometry | 1 | 1999 | 12 | 0.180 |
Why?
|
Echo-Planar Imaging | 1 | 1999 | 16 | 0.180 |
Why?
|
Follow-Up Studies | 9 | 2019 | 2106 | 0.180 |
Why?
|
Cerebral Infarction | 1 | 1999 | 24 | 0.180 |
Why?
|
Mass Media | 1 | 2019 | 12 | 0.180 |
Why?
|
Cause of Death | 2 | 2017 | 219 | 0.180 |
Why?
|
Image Enhancement | 1 | 1999 | 70 | 0.170 |
Why?
|
Thyroxine | 2 | 2009 | 16 | 0.170 |
Why?
|
Polysomnography | 6 | 2017 | 32 | 0.170 |
Why?
|
Disabled Persons | 1 | 1999 | 83 | 0.170 |
Why?
|
Consensus | 1 | 2018 | 68 | 0.170 |
Why?
|
Risk Assessment | 8 | 2018 | 1300 | 0.160 |
Why?
|
Lipoproteins | 2 | 2009 | 82 | 0.160 |
Why?
|
Sensitivity and Specificity | 7 | 2018 | 531 | 0.160 |
Why?
|
Adolescent | 13 | 2019 | 3248 | 0.160 |
Why?
|
Patient Care Planning | 2 | 2017 | 53 | 0.150 |
Why?
|
Sleep | 2 | 2014 | 84 | 0.150 |
Why?
|
Cerebrovascular Disorders | 1 | 1997 | 48 | 0.150 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 207 | 0.150 |
Why?
|
Infant, Premature, Diseases | 1 | 1997 | 22 | 0.150 |
Why?
|
Cerebral Hemorrhage | 1 | 1997 | 62 | 0.150 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2015 | 462 | 0.140 |
Why?
|
Dental Implantation, Endosseous | 1 | 1996 | 4 | 0.140 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 2016 | 15 | 0.140 |
Why?
|
Dental Implants | 1 | 1996 | 6 | 0.140 |
Why?
|
Triglycerides | 5 | 2009 | 214 | 0.140 |
Why?
|
Proportional Hazards Models | 4 | 2019 | 706 | 0.140 |
Why?
|
C-Reactive Protein | 2 | 2010 | 229 | 0.140 |
Why?
|
Sports Medicine | 1 | 1996 | 23 | 0.140 |
Why?
|
Mandible | 1 | 1996 | 37 | 0.140 |
Why?
|
Brachial Artery | 2 | 2007 | 66 | 0.140 |
Why?
|
Fractures, Bone | 1 | 2017 | 149 | 0.130 |
Why?
|
Vasodilation | 2 | 2007 | 87 | 0.130 |
Why?
|
Physical Fitness | 1 | 2016 | 119 | 0.130 |
Why?
|
Heart Failure | 2 | 2017 | 567 | 0.130 |
Why?
|
Scapula | 1 | 1995 | 18 | 0.130 |
Why?
|
Body Mass Index | 6 | 2016 | 862 | 0.130 |
Why?
|
Time Factors | 6 | 2017 | 1997 | 0.130 |
Why?
|
Aging | 2 | 1999 | 880 | 0.130 |
Why?
|
Cocaine | 2 | 1995 | 262 | 0.120 |
Why?
|
Caffeine | 1 | 1994 | 31 | 0.120 |
Why?
|
Alzheimer Disease | 1 | 1997 | 312 | 0.120 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2010 | 180 | 0.120 |
Why?
|
Intracranial Embolism and Thrombosis | 3 | 1998 | 3 | 0.120 |
Why?
|
Software | 3 | 2005 | 109 | 0.120 |
Why?
|
Prospective Studies | 6 | 2003 | 2010 | 0.110 |
Why?
|
Cardiopulmonary Bypass | 3 | 1998 | 57 | 0.110 |
Why?
|
Estrogens | 2 | 2007 | 162 | 0.110 |
Why?
|
Shoulder Joint | 1 | 1995 | 123 | 0.110 |
Why?
|
Depressive Disorder, Major | 1 | 2012 | 35 | 0.110 |
Why?
|
Behavior, Animal | 1 | 1994 | 264 | 0.110 |
Why?
|
Logistic Models | 4 | 2006 | 725 | 0.110 |
Why?
|
Apolipoproteins | 1 | 2014 | 196 | 0.110 |
Why?
|
Receptors, Estrogen | 2 | 2002 | 89 | 0.100 |
Why?
|
Internship and Residency | 1 | 1995 | 283 | 0.100 |
Why?
|
Stroke | 2 | 2017 | 522 | 0.100 |
Why?
|
Potassium, Dietary | 2 | 2001 | 5 | 0.100 |
Why?
|
Cholesterol | 3 | 2008 | 229 | 0.100 |
Why?
|
Diabetic Angiopathies | 1 | 2012 | 137 | 0.100 |
Why?
|
Sodium, Dietary | 2 | 2001 | 24 | 0.100 |
Why?
|
Tomography, X-Ray Computed | 1 | 1996 | 871 | 0.100 |
Why?
|
Child | 7 | 2003 | 2209 | 0.100 |
Why?
|
International Cooperation | 1 | 2010 | 25 | 0.090 |
Why?
|
Genetic Predisposition to Disease | 3 | 2009 | 836 | 0.090 |
Why?
|
HLA Antigens | 1 | 2010 | 35 | 0.090 |
Why?
|
Phenotype | 6 | 2009 | 629 | 0.090 |
Why?
|
Erythrocyte Count | 1 | 2009 | 6 | 0.090 |
Why?
|
Asian Americans | 2 | 2007 | 98 | 0.090 |
Why?
|
North Carolina | 4 | 2003 | 1422 | 0.090 |
Why?
|
Prevalence | 6 | 2012 | 892 | 0.090 |
Why?
|
Age Factors | 5 | 2018 | 1105 | 0.090 |
Why?
|
Survival Analysis | 2 | 2018 | 440 | 0.090 |
Why?
|
DNA | 2 | 2008 | 204 | 0.090 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2009 | 52 | 0.090 |
Why?
|
Liver Diseases | 2 | 2006 | 61 | 0.090 |
Why?
|
Behavior Therapy | 1 | 2009 | 89 | 0.090 |
Why?
|
Hormones | 1 | 2008 | 19 | 0.090 |
Why?
|
Indians, North American | 2 | 2006 | 108 | 0.090 |
Why?
|
Thyrotropin | 1 | 2008 | 9 | 0.080 |
Why?
|
Observer Variation | 3 | 1998 | 96 | 0.080 |
Why?
|
Patient Education as Topic | 3 | 2016 | 251 | 0.080 |
Why?
|
Drug Therapy, Combination | 3 | 2004 | 273 | 0.080 |
Why?
|
Adolescent Behavior | 2 | 1999 | 57 | 0.080 |
Why?
|
Iron-Binding Proteins | 1 | 2007 | 4 | 0.080 |
Why?
|
Erythrocyte Indices | 1 | 2007 | 3 | 0.080 |
Why?
|
Prognosis | 3 | 2018 | 1362 | 0.080 |
Why?
|
Albuminuria | 1 | 2009 | 174 | 0.080 |
Why?
|
Hemoglobins | 1 | 2007 | 42 | 0.080 |
Why?
|
Health Status | 2 | 2016 | 368 | 0.080 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2009 | 1079 | 0.080 |
Why?
|
Oceanic Ancestry Group | 1 | 2007 | 7 | 0.080 |
Why?
|
Contraceptive Agents, Female | 1 | 2007 | 15 | 0.080 |
Why?
|
E-Selectin | 2 | 2008 | 20 | 0.080 |
Why?
|
Sleep Apnea Syndromes | 2 | 1998 | 26 | 0.080 |
Why?
|
Hospitalization | 3 | 2001 | 417 | 0.070 |
Why?
|
Infant, Newborn | 3 | 1997 | 595 | 0.070 |
Why?
|
Coronary Angiography | 5 | 2008 | 136 | 0.070 |
Why?
|
Predictive Value of Tests | 4 | 2014 | 784 | 0.070 |
Why?
|
Glomerular Filtration Rate | 2 | 2018 | 286 | 0.070 |
Why?
|
Up-Regulation | 1 | 2007 | 183 | 0.070 |
Why?
|
Continental Population Groups | 1 | 2007 | 221 | 0.070 |
Why?
|
Anthropometry | 2 | 2017 | 82 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2017 | 641 | 0.070 |
Why?
|
Systole | 2 | 2017 | 87 | 0.070 |
Why?
|
Sex Factors | 4 | 2018 | 626 | 0.070 |
Why?
|
African Continental Ancestry Group | 2 | 2005 | 350 | 0.070 |
Why?
|
Forecasting | 2 | 2003 | 133 | 0.060 |
Why?
|
Hormone Replacement Therapy | 2 | 2002 | 86 | 0.060 |
Why?
|
Double-Blind Method | 5 | 2007 | 501 | 0.060 |
Why?
|
African Americans | 2 | 2014 | 1373 | 0.060 |
Why?
|
Reference Standards | 2 | 2017 | 30 | 0.060 |
Why?
|
Cross-Sectional Studies | 4 | 2012 | 1353 | 0.060 |
Why?
|
Adaptation, Psychological | 2 | 2003 | 125 | 0.060 |
Why?
|
Administration, Oral | 1 | 2004 | 169 | 0.060 |
Why?
|
Nutritional Status | 2 | 2001 | 68 | 0.060 |
Why?
|
Microcirculation | 3 | 1998 | 61 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2006 | 360 | 0.060 |
Why?
|
Utilization Review | 1 | 2003 | 16 | 0.060 |
Why?
|
Combined Modality Therapy | 1 | 2004 | 524 | 0.060 |
Why?
|
Patient Selection | 2 | 2003 | 257 | 0.060 |
Why?
|
Odds Ratio | 3 | 2012 | 446 | 0.060 |
Why?
|
Ethnic Groups | 4 | 2009 | 440 | 0.050 |
Why?
|
Factor V | 1 | 2002 | 6 | 0.050 |
Why?
|
Depressive Disorder | 2 | 2000 | 74 | 0.050 |
Why?
|
Thromboembolism | 1 | 2002 | 30 | 0.050 |
Why?
|
Young Adult | 2 | 2019 | 2398 | 0.050 |
Why?
|
Venous Thrombosis | 1 | 2002 | 48 | 0.050 |
Why?
|
Kidney Failure, Chronic | 2 | 2017 | 518 | 0.050 |
Why?
|
Gene Frequency | 3 | 2007 | 225 | 0.050 |
Why?
|
Reference Values | 2 | 2014 | 224 | 0.050 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 1998 | 76 | 0.050 |
Why?
|
Women's Health | 1 | 2003 | 226 | 0.050 |
Why?
|
Blood Glucose | 2 | 2017 | 465 | 0.050 |
Why?
|
Ethanol | 1 | 2003 | 185 | 0.050 |
Why?
|
Problem Solving | 1 | 2001 | 27 | 0.050 |
Why?
|
Alcohol Drinking | 1 | 2003 | 243 | 0.050 |
Why?
|
Longitudinal Studies | 2 | 2001 | 708 | 0.050 |
Why?
|
Heliotherapy | 2 | 1997 | 3 | 0.050 |
Why?
|
Social Environment | 1 | 2001 | 74 | 0.050 |
Why?
|
Alkaline Phosphatase | 2 | 1998 | 36 | 0.050 |
Why?
|
Histocytochemistry | 2 | 1998 | 30 | 0.050 |
Why?
|
Lipids | 2 | 2000 | 208 | 0.050 |
Why?
|
Medroxyprogesterone | 1 | 2000 | 12 | 0.050 |
Why?
|
Progesterone Congeners | 1 | 2000 | 15 | 0.050 |
Why?
|
Liver | 1 | 2003 | 464 | 0.050 |
Why?
|
Arteriosclerosis | 1 | 2000 | 116 | 0.050 |
Why?
|
Likelihood Functions | 1 | 1999 | 38 | 0.040 |
Why?
|
Self Administration | 3 | 1997 | 296 | 0.040 |
Why?
|
California | 1 | 1999 | 60 | 0.040 |
Why?
|
Memory | 1 | 2001 | 187 | 0.040 |
Why?
|
Health Status Indicators | 1 | 1999 | 67 | 0.040 |
Why?
|
Waist Circumference | 2 | 2009 | 88 | 0.040 |
Why?
|
Placebos | 2 | 2008 | 61 | 0.040 |
Why?
|
Adolescent, Hospitalized | 1 | 1998 | 1 | 0.040 |
Why?
|
Acute Disease | 1 | 1999 | 239 | 0.040 |
Why?
|
Blood Transfusion, Autologous | 1 | 1998 | 3 | 0.040 |
Why?
|
Reproducibility of Results | 4 | 2006 | 724 | 0.040 |
Why?
|
Suction | 1 | 1998 | 13 | 0.040 |
Why?
|
Sleep Stages | 2 | 2014 | 6 | 0.040 |
Why?
|
Canada | 2 | 2008 | 48 | 0.040 |
Why?
|
Silicon | 1 | 1998 | 2 | 0.040 |
Why?
|
Aluminum | 1 | 1998 | 4 | 0.040 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2018 | 26 | 0.040 |
Why?
|
Urban Population | 1 | 1998 | 79 | 0.040 |
Why?
|
Mutation, Missense | 2 | 2008 | 48 | 0.040 |
Why?
|
Treatment Refusal | 1 | 1997 | 10 | 0.040 |
Why?
|
Confidence Intervals | 1 | 2018 | 140 | 0.040 |
Why?
|
Chronic Disease | 1 | 1999 | 369 | 0.040 |
Why?
|
Receptors, Transferrin | 2 | 2008 | 10 | 0.040 |
Why?
|
Gastric Acidity Determination | 1 | 1997 | 4 | 0.040 |
Why?
|
Antimicrobial Cationic Peptides | 2 | 2008 | 14 | 0.040 |
Why?
|
Referral and Consultation | 1 | 1998 | 113 | 0.040 |
Why?
|
Monitoring, Ambulatory | 1 | 1997 | 8 | 0.040 |
Why?
|
Gastroesophageal Reflux | 1 | 1997 | 25 | 0.040 |
Why?
|
Cardiac Surgical Procedures | 1 | 1998 | 71 | 0.040 |
Why?
|
Liver Function Tests | 2 | 2007 | 19 | 0.040 |
Why?
|
Drug Administration Schedule | 1 | 2017 | 246 | 0.040 |
Why?
|
Cerebral Arteries | 1 | 1997 | 18 | 0.040 |
Why?
|
Office Visits | 1 | 2017 | 71 | 0.040 |
Why?
|
Veins | 1 | 1997 | 29 | 0.040 |
Why?
|
Rural Population | 1 | 1998 | 244 | 0.040 |
Why?
|
Recurrence | 3 | 2008 | 235 | 0.040 |
Why?
|
Infant, Very Low Birth Weight | 1 | 1997 | 47 | 0.040 |
Why?
|
Infant, Premature | 1 | 1997 | 62 | 0.040 |
Why?
|
Cognition | 1 | 2001 | 524 | 0.040 |
Why?
|
Sex Distribution | 2 | 2008 | 185 | 0.040 |
Why?
|
Cognition Disorders | 1 | 2000 | 389 | 0.040 |
Why?
|
Case-Control Studies | 3 | 2008 | 855 | 0.040 |
Why?
|
Critical Care | 1 | 2017 | 114 | 0.040 |
Why?
|
Home Nursing | 1 | 1996 | 10 | 0.040 |
Why?
|
Animals | 6 | 2003 | 7297 | 0.040 |
Why?
|
Renal Replacement Therapy | 1 | 1996 | 16 | 0.040 |
Why?
|
Respiratory Physiological Phenomena | 1 | 2016 | 6 | 0.040 |
Why?
|
Alveolectomy | 1 | 1996 | 1 | 0.040 |
Why?
|
Incisor | 1 | 1996 | 1 | 0.040 |
Why?
|
Jaw, Edentulous | 1 | 1996 | 2 | 0.040 |
Why?
|
Bicuspid | 1 | 1996 | 2 | 0.040 |
Why?
|
Molar | 1 | 1996 | 3 | 0.040 |
Why?
|
Estrogen Receptor alpha | 2 | 2009 | 50 | 0.040 |
Why?
|
Alveolar Process | 1 | 1996 | 5 | 0.040 |
Why?
|
Titanium | 1 | 1996 | 9 | 0.040 |
Why?
|
Subtraction Technique | 1 | 1996 | 12 | 0.030 |
Why?
|
Ultraviolet Therapy | 1 | 1996 | 39 | 0.030 |
Why?
|
Radiographic Image Enhancement | 1 | 1996 | 30 | 0.030 |
Why?
|
Patient Admission | 1 | 1996 | 53 | 0.030 |
Why?
|
Complementary Therapies | 1 | 1996 | 75 | 0.030 |
Why?
|
Goals | 1 | 2015 | 36 | 0.030 |
Why?
|
Regression Analysis | 3 | 2003 | 272 | 0.030 |
Why?
|
Acute Coronary Syndrome | 1 | 2017 | 175 | 0.030 |
Why?
|
Depression | 2 | 2012 | 378 | 0.030 |
Why?
|
Apnea | 1 | 2014 | 6 | 0.030 |
Why?
|
Education, Medical, Graduate | 1 | 1995 | 116 | 0.030 |
Why?
|
Sodium Chloride Symporter Inhibitors | 1 | 2014 | 10 | 0.030 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 1 | 2014 | 10 | 0.030 |
Why?
|
Equipment and Supplies | 1 | 1994 | 15 | 0.030 |
Why?
|
Calcium Channel Blockers | 1 | 2014 | 49 | 0.030 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2014 | 59 | 0.030 |
Why?
|
Reinforcement Schedule | 1 | 1994 | 60 | 0.030 |
Why?
|
Nucleus Accumbens | 1 | 1995 | 92 | 0.030 |
Why?
|
Incidence | 1 | 2017 | 1105 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2014 | 95 | 0.030 |
Why?
|
Single-Blind Method | 1 | 1994 | 165 | 0.030 |
Why?
|
Diet | 2 | 2012 | 348 | 0.030 |
Why?
|
Conditioning, Operant | 1 | 1994 | 96 | 0.030 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 134 | 0.030 |
Why?
|
Linear Models | 1 | 2014 | 425 | 0.030 |
Why?
|
Myocardial Infarction | 1 | 2017 | 412 | 0.030 |
Why?
|
Disease Progression | 2 | 2008 | 572 | 0.030 |
Why?
|
Treatment Failure | 1 | 2013 | 159 | 0.030 |
Why?
|
Dogs | 3 | 1998 | 117 | 0.030 |
Why?
|
Macaca mulatta | 1 | 1994 | 322 | 0.030 |
Why?
|
Genetic Variation | 1 | 2014 | 251 | 0.030 |
Why?
|
Remission Induction | 1 | 2012 | 78 | 0.030 |
Why?
|
Primary Health Care | 2 | 2006 | 178 | 0.030 |
Why?
|
Motor Activity | 1 | 1995 | 310 | 0.030 |
Why?
|
Dopamine | 1 | 1995 | 226 | 0.030 |
Why?
|
Endothelium, Vascular | 2 | 2007 | 145 | 0.030 |
Why?
|
Heart Rate | 1 | 1994 | 315 | 0.030 |
Why?
|
Wounds and Injuries | 1 | 1995 | 249 | 0.030 |
Why?
|
Feeding Behavior | 1 | 2013 | 159 | 0.030 |
Why?
|
Potassium | 2 | 2001 | 37 | 0.020 |
Why?
|
Sodium | 2 | 2001 | 37 | 0.020 |
Why?
|
Weight Gain | 1 | 2012 | 108 | 0.020 |
Why?
|
Biological Assay | 1 | 2010 | 15 | 0.020 |
Why?
|
Education | 1 | 2010 | 30 | 0.020 |
Why?
|
Quality Control | 1 | 2010 | 38 | 0.020 |
Why?
|
Clinical Laboratory Techniques | 1 | 2010 | 18 | 0.020 |
Why?
|
Pedigree | 1 | 2010 | 133 | 0.020 |
Why?
|
North America | 1 | 2009 | 33 | 0.020 |
Why?
|
Cell Size | 1 | 2009 | 32 | 0.020 |
Why?
|
Electrocardiography | 1 | 1994 | 562 | 0.020 |
Why?
|
Cholesterol Ester Transfer Proteins | 1 | 2009 | 11 | 0.020 |
Why?
|
Scavenger Receptors, Class B | 1 | 2009 | 12 | 0.020 |
Why?
|
Lipoprotein Lipase | 1 | 2009 | 14 | 0.020 |
Why?
|
Lipase | 1 | 2009 | 28 | 0.020 |
Why?
|
Attitude to Health | 2 | 2003 | 147 | 0.020 |
Why?
|
Lipid Metabolism | 1 | 2009 | 100 | 0.020 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2009 | 60 | 0.020 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 17 | 0.020 |
Why?
|
Cohort Studies | 2 | 2008 | 1674 | 0.020 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2008 | 41 | 0.020 |
Why?
|
Hyperthyroidism | 1 | 2008 | 3 | 0.020 |
Why?
|
Epidemiologic Measurements | 1 | 2008 | 2 | 0.020 |
Why?
|
Statistics as Topic | 2 | 1999 | 106 | 0.020 |
Why?
|
Phlebotomy | 1 | 2008 | 17 | 0.020 |
Why?
|
Hypothyroidism | 1 | 2008 | 12 | 0.020 |
Why?
|
Age Distribution | 1 | 2008 | 197 | 0.020 |
Why?
|
Sequence Deletion | 1 | 2008 | 36 | 0.020 |
Why?
|
Alleles | 1 | 2008 | 251 | 0.020 |
Why?
|
Body Weight | 1 | 2009 | 290 | 0.020 |
Why?
|
Probability | 1 | 2008 | 150 | 0.020 |
Why?
|
Genetic Markers | 1 | 2007 | 122 | 0.020 |
Why?
|
Models, Genetic | 1 | 2007 | 92 | 0.020 |
Why?
|
Apoferritins | 1 | 2007 | 4 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2008 | 212 | 0.020 |
Why?
|
Arterioles | 2 | 1998 | 12 | 0.020 |
Why?
|
Regional Blood Flow | 1 | 2007 | 82 | 0.020 |
Why?
|
Algorithms | 1 | 2010 | 461 | 0.020 |
Why?
|
Capillaries | 2 | 1998 | 23 | 0.020 |
Why?
|
Asian Continental Ancestry Group | 1 | 2007 | 110 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2007 | 67 | 0.020 |
Why?
|
Molecular Epidemiology | 1 | 2006 | 20 | 0.020 |
Why?
|
Evaluation Studies as Topic | 2 | 1996 | 39 | 0.020 |
Why?
|
Adipose Tissue | 1 | 2009 | 327 | 0.020 |
Why?
|
Survival Rate | 1 | 2008 | 795 | 0.020 |
Why?
|
ROC Curve | 1 | 2005 | 148 | 0.020 |
Why?
|
Arthritis | 1 | 2005 | 37 | 0.020 |
Why?
|
Protein Binding | 1 | 2005 | 199 | 0.020 |
Why?
|
Ultrasonography | 1 | 2007 | 345 | 0.020 |
Why?
|
Heart Diseases | 1 | 2005 | 97 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2005 | 171 | 0.010 |
Why?
|
Genetic Counseling | 1 | 2003 | 7 | 0.010 |
Why?
|
Urinary Incontinence | 1 | 2003 | 45 | 0.010 |
Why?
|
Transcriptional Activation | 1 | 2002 | 42 | 0.010 |
Why?
|
Macaca fascicularis | 1 | 2003 | 389 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2002 | 138 | 0.010 |
Why?
|
Social Support | 1 | 2003 | 163 | 0.010 |
Why?
|
Base Sequence | 1 | 2002 | 240 | 0.010 |
Why?
|
Epidemiologic Studies | 1 | 2001 | 20 | 0.010 |
Why?
|
Health Behavior | 1 | 2003 | 212 | 0.010 |
Why?
|
Urinalysis | 1 | 2001 | 19 | 0.010 |
Why?
|
Risk | 1 | 2002 | 289 | 0.010 |
Why?
|
Self Disclosure | 1 | 2001 | 23 | 0.010 |
Why?
|
Retrospective Studies | 2 | 1998 | 3107 | 0.010 |
Why?
|
Costs and Cost Analysis | 1 | 2001 | 88 | 0.010 |
Why?
|
Affect | 1 | 2001 | 63 | 0.010 |
Why?
|
Functional Laterality | 1 | 2000 | 59 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2001 | 126 | 0.010 |
Why?
|
Memory Disorders | 1 | 2000 | 61 | 0.010 |
Why?
|
Patient Discharge | 1 | 2001 | 168 | 0.010 |
Why?
|
Virginia | 1 | 1999 | 64 | 0.010 |
Why?
|
Dilatation, Pathologic | 1 | 1998 | 19 | 0.010 |
Why?
|
Hypothermia, Induced | 1 | 1998 | 16 | 0.010 |
Why?
|
Vasculitis | 1 | 1998 | 23 | 0.010 |
Why?
|
Lasers | 1 | 1998 | 19 | 0.010 |
Why?
|
Work | 1 | 1997 | 7 | 0.010 |
Why?
|
Financing, Personal | 1 | 1997 | 6 | 0.010 |
Why?
|
Absenteeism | 1 | 1997 | 11 | 0.010 |
Why?
|
Family Characteristics | 1 | 1997 | 32 | 0.010 |
Why?
|
Mass Spectrometry | 1 | 1998 | 99 | 0.010 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 1998 | 41 | 0.010 |
Why?
|
Self Concept | 1 | 1997 | 41 | 0.010 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1997 | 66 | 0.010 |
Why?
|
Cost of Illness | 1 | 1997 | 63 | 0.010 |
Why?
|
Income | 1 | 1997 | 51 | 0.010 |
Why?
|
Ultraviolet Rays | 1 | 1997 | 46 | 0.010 |
Why?
|
Coronary Artery Bypass | 1 | 1998 | 100 | 0.010 |
Why?
|
Health Expenditures | 1 | 1997 | 61 | 0.010 |
Why?
|
Smoking | 1 | 2000 | 427 | 0.010 |
Why?
|
Crisis Intervention | 1 | 1996 | 1 | 0.010 |
Why?
|
Phytotherapy | 1 | 1996 | 38 | 0.010 |
Why?
|
Personality Assessment | 1 | 1996 | 6 | 0.010 |
Why?
|
Health Care Costs | 1 | 1997 | 108 | 0.010 |
Why?
|
Self Care | 1 | 1997 | 136 | 0.010 |
Why?
|
Activities of Daily Living | 1 | 1997 | 237 | 0.010 |
Why?
|
Arthritis, Psoriatic | 1 | 1996 | 25 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 1997 | 385 | 0.010 |
Why?
|
Vitamins | 1 | 1996 | 58 | 0.010 |
Why?
|
Electrooculography | 1 | 1995 | 2 | 0.010 |
Why?
|
Data Collection | 1 | 1996 | 163 | 0.010 |
Why?
|
Arousal | 1 | 1995 | 19 | 0.010 |
Why?
|
Anxiety Disorders | 1 | 1996 | 60 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 1997 | 222 | 0.010 |
Why?
|
3,4-Dihydroxyphenylacetic Acid | 1 | 1995 | 3 | 0.010 |
Why?
|
Homovanillic Acid | 1 | 1995 | 11 | 0.010 |
Why?
|
Skin | 1 | 1997 | 203 | 0.010 |
Why?
|
Mortality | 1 | 1996 | 108 | 0.010 |
Why?
|
Rats, Inbred F344 | 1 | 1995 | 125 | 0.010 |
Why?
|
Length of Stay | 1 | 1996 | 291 | 0.010 |
Why?
|
Pilot Projects | 1 | 1996 | 469 | 0.010 |
Why?
|
Infant | 1 | 1997 | 967 | 0.010 |
Why?
|
Child, Preschool | 1 | 1997 | 1164 | 0.010 |
Why?
|
Rats | 1 | 1995 | 1604 | 0.010 |
Why?
|